Identification of novel OCRL isoforms associated with phenotypic differences between Dent disease-2 and Lowe syndrome.


Journal

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
ISSN: 1460-2385
Titre abrégé: Nephrol Dial Transplant
Pays: England
ID NLM: 8706402

Informations de publication

Date de publication:
25 01 2022
Historique:
received: 18 06 2021
pubmed: 30 9 2021
medline: 23 3 2022
entrez: 29 9 2021
Statut: ppublish

Résumé

Although Lowe syndrome and Dent disease-2 are caused by Oculocerebrorenal syndrome of Lowe (OCRL) mutations, their clinical severities differ substantially and their molecular mechanisms remain unclear. Truncating mutations in OCRL exons 1-7 lead to Dent disease-2, whereas those in exons 8-24 lead to Lowe syndrome. Herein we identified the mechanism underlying the action of novel OCRL protein isoforms. Messenger RNA samples extracted from cultured urine-derived cells from a healthy control and a Dent disease-2 patient were examined to detect the 5' end of the OCRL isoform. For protein expression and functional analysis, vectors containing the full-length OCRL transcripts, the isoform transcripts and transcripts with truncating mutations detected in Lowe syndrome and Dent disease-2 patients were transfected into HeLa cells. We successfully cloned the novel isoform transcripts from OCRL exons 6-24, including the translation-initiation codons present in exon 8. In vitro protein-expression analysis detected proteins of two different sizes (105 and 80 kDa) translated from full-length OCRL, whereas only one protein (80 kDa) was found from the isoform and Dent disease-2 variants. No protein expression was observed for the Lowe syndrome variants. The isoform enzyme activity was equivalent to that of full-length OCRL; the Dent disease-2 variants retained >50% enzyme activity, whereas the Lowe syndrome variants retained <20% activity. We elucidated the molecular mechanism underlying the two different phenotypes in OCRL-related diseases; the functional OCRL isoform translated starting at exon 8 was associated with this mechanism.

Sections du résumé

BACKGROUND
Although Lowe syndrome and Dent disease-2 are caused by Oculocerebrorenal syndrome of Lowe (OCRL) mutations, their clinical severities differ substantially and their molecular mechanisms remain unclear. Truncating mutations in OCRL exons 1-7 lead to Dent disease-2, whereas those in exons 8-24 lead to Lowe syndrome. Herein we identified the mechanism underlying the action of novel OCRL protein isoforms.
METHODS
Messenger RNA samples extracted from cultured urine-derived cells from a healthy control and a Dent disease-2 patient were examined to detect the 5' end of the OCRL isoform. For protein expression and functional analysis, vectors containing the full-length OCRL transcripts, the isoform transcripts and transcripts with truncating mutations detected in Lowe syndrome and Dent disease-2 patients were transfected into HeLa cells.
RESULTS
We successfully cloned the novel isoform transcripts from OCRL exons 6-24, including the translation-initiation codons present in exon 8. In vitro protein-expression analysis detected proteins of two different sizes (105 and 80 kDa) translated from full-length OCRL, whereas only one protein (80 kDa) was found from the isoform and Dent disease-2 variants. No protein expression was observed for the Lowe syndrome variants. The isoform enzyme activity was equivalent to that of full-length OCRL; the Dent disease-2 variants retained >50% enzyme activity, whereas the Lowe syndrome variants retained <20% activity.
CONCLUSIONS
We elucidated the molecular mechanism underlying the two different phenotypes in OCRL-related diseases; the functional OCRL isoform translated starting at exon 8 was associated with this mechanism.

Identifiants

pubmed: 34586410
pii: 6377826
doi: 10.1093/ndt/gfab274
doi:

Substances chimiques

Protein Isoforms 0
Phosphoric Monoester Hydrolases EC 3.1.3.2
OCRL protein, human EC 3.1.3.36

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

262-270

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press on behalf of the ERA.

Auteurs

Nana Sakakibara (N)

Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan.

Takeshi Ijuin (T)

Division of Biochemistry, Kobe University Graduate School of Medicine, Kobe, Japan.

Tomoko Horinouchi (T)

Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan.

Tomohiko Yamamura (T)

Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan.

China Nagano (C)

Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan.

Eri Okada (E)

Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan.
Department of Nephrology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.

Shinya Ishiko (S)

Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan.

Yuya Aoto (Y)

Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan.

Rini Rossanti (R)

Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan.

Takeshi Ninchoji (T)

Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan.

Hiroyuki Awano (H)

Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan.

Hiroaki Nagase (H)

Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan.

Shogo Minamikawa (S)

Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan.

Ryojiro Tanaka (R)

Department of Nephrology, Hyogo Prefectural Kobe Children's Hospital, Kobe, Japan.

Takeshi Matsuyama (T)

Department of Pediatrics, Fussa Hospital, Tokyo, Japan.

Koji Nagatani (K)

Department of Pediatrics, Uwajima City Hospital, Uwajima, Japan.

Koichi Kamei (K)

Division of Nephrology and Rheumatology, National Center for Child Health and Development, Tokyo, Japan.

Kumiko Jinnouchi (K)

Department of Pediatrics, Faculty of Medicine, Saga University, Saga, Japan.

Yasufumi Ohtsuka (Y)

Department of Pediatrics, Faculty of Medicine, Saga University, Saga, Japan.

Masafumi Oka (M)

Department of Pediatrics, Faculty of Medicine, Saga University, Saga, Japan.

Yoshinori Araki (Y)

Department of Pediatrics, National Hospital Organization Hokkaido Medical Center, Sapporo, Japan.

Toju Tanaka (T)

Department of Pediatrics, National Hospital Organization Hokkaido Medical Center, Sapporo, Japan.

Mari S Harada (MS)

Department of Pediatrics, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.

Toru Igarashi (T)

Department of Pediatrics, Nippon Medical School Hospital, Tokyo, Japan.

Hikaru Kitahara (H)

Department of Pediatrics, Osaka Medical College, Takatsuki, Japan.

Naoya Morisada (N)

Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan.
Department of Clinical Genetics, Hyogo Prefectural Kobe Children's Hospital, Kobe, Japan.

Shun-Ichi Nakamura (SI)

Division of Biochemistry, Kobe University Graduate School of Medicine, Kobe, Japan.

Taro Okada (T)

Division of Biochemistry, Kobe University Graduate School of Medicine, Kobe, Japan.

Kazumoto Iijima (K)

Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan.

Kandai Nozu (K)

Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH